Drug interactions with antiretrovirals

Morse, Gene D.

doi:10.1007/s11908-000-0043-7

Cited by 6 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are numerous well-documented interactions with drugs used to treat opioid dependence, such as methadone and l-a-acetylmethadol, and particularly with antiretroviral drugs [33][34][35]. However, before the conduct of systematic investigations, clinical anecdotal and adverse outcomes were, unfortunately, the most common method of learning of methadone drug interactions [36].…”

Section: Considerations Regarding Translation Of In Vitro To Clinicalmentioning

confidence: 99%

Pharmacokinetic Interactions between Buprenorphine and Antiretroviral Medications

Bruce¹,

McCance‐Katz²,

Kharasch³

et al. 2006

Clinical Infectious Diseases

Self Cite

View full text Add to dashboard Cite

Buprenorphine is used for the treatment of opioid dependence. As the number of persons receiving buprenorphine treatment and antiretroviral therapy continues to grow, so too does the existence and clinical impact of drug interactions between buprenorphine and medications for treating human immunodeficiency virus (HIV) infection. Awareness that such interactions exist may deter some patients and physicians from initiating potentially lifesaving therapy or lead to complications among patients whose treatment is already under way. Complications include nonadherence to antiretroviral therapy and the development of viral resistance. Illicit drug use is a frequent consequence of adverse drug effects experienced by injection drug users. The occurrence of unrecognized drug interactions can lead to unsuccessful therapy for HIV infection and the treatment of substance dependence. The present review is organized to provide a working background of buprenorphine pharmacology. Review of the current state of knowledge regarding specific interactions between buprenorphine and antiretrovirals is followed by a review of the clinical applicability of these interactions.

show abstract

Section: Considerations Regarding Translation Of In Vitro To Clinicalmentioning

confidence: 99%

Pharmacokinetic Interactions between Buprenorphine and Antiretroviral Medications

Bruce¹,

McCance‐Katz²,

Kharasch³

et al. 2006

Clinical Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

A Randomized Trial of 2 Different 4‐Drug Antiretroviral Regimens versus a 3‐Drug Regimen, in Advanced Human Immunodeficiency Virus Disease

et al. 2003

View full text Add to dashboard Cite

To compare long-term virologic benefits of antiretroviral regimens in persons with advanced human immunodeficiency virus (HIV) disease, a randomized, open-label study was conducted of 517 subjects with no or limited previous experience with antiretroviral therapy. Subjects received lamivudine plus zidovudine and indinavir (indinavir group), efavirenz plus indinavir (efavirenz + indinavir group), or nelfinavir plus indinavir (nelfinavir + indinavir group) and were monitored for 2.1 years. Virologic failure was lower in the efavirenz + indinavir group (P=.04) and higher in the nelfinavir + indinavir group (P=.006), compared with that in the indinavir group. No difference in grade 3 or 4 adverse event rates in the efavirenz + indinavir group (P=.97) and a trend toward an increased rate in the nelfinavir + indinavir group (P=.07), compared with the indinavir group, were noted. A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity.

show abstract